Methylphenidate HCL ER Tablets Solicitation
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-24-R-0014
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents4
The presolicitation notice titled "Methylphenidate HCL ER Tablets Solicitation" (Procurement Identifier: SPE2D2-24-R-0014) announces an upcoming contract opportunity managed by DLA Troop Support, a federal office responsible for providing logistical support to military and other government entities. The procurement falls under NAICS Code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified by Product Service Code 6505, indicating a focus on drugs and biologicals.
The primary objective of this solicitation is to secure a reliable supply of Methylphenidate Hydrochloride Extended Release (ER) tablets, a pharmaceutical product commonly used in the treatment of attention deficit hyperactivity disorder (ADHD) and certain other medical conditions. The intended outcome is to ensure that the contracting entity, DLA Troop Support, can meet the ongoing needs of its stakeholders for this critical medication, maintaining continuity of care and operational readiness.
Key requirements for this procurement include the manufacturing and delivery of Methylphenidate HCL ER tablets in accordance with applicable federal standards and regulations. Contractors must demonstrate capabilities in pharmaceutical production, quality assurance, and regulatory compliance as defined by the NAICS classification. The solicitation is expected to outline specific product specifications, packaging, labeling, and delivery schedules, although these details are not provided in the current notice.
The contract has been awarded to SpecGX under award number SPE2D2-25-D-0003, indicating that the competitive process has concluded and the selected vendor will be responsible for fulfilling the contract requirements. While the notice is marked as "ACTIVE," it primarily serves as a presolicitation announcement and confirmation of award.
Interested parties seeking further information or clarification may contact the designated representatives at DLA Troop Support. The primary contact is Courtney Hunter-Stangler ([email protected], 215-737-6845), and the secondary contact is Jason C. Wray ([email protected], 215-737-0614). The notice was posted on November 12, 2024, with a response date listed as January 8, 2024.
The solicitation is accessible via the official SAM.gov portal (Opportunity ID: c26fad1ba1cc433283e1f4c734ebb872), where additional attachments and documentation may be available for review. Contractors evaluating this opportunity should note the federal procurement context, the pharmaceutical manufacturing requirements, and the importance of compliance with all relevant standards throughout the contract lifecycle.
No information regarding set-aside requirements, special considerations, or specific deliverable quantities is provided in the current notice. Contractors are encouraged to consult the SAM.gov listing and reach out to the listed contacts for any further details that may impact their eligibility or ability to perform under this contract.